CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.
|Strength||140 mg capsule|
|Indication||Mantle Cell Lymphoma|
|Funding Request||For the treatment of patients with relapsed/refractory mantle cell lymphoma (MCL)|
|Pre Noc Submission||No|
|NOC Date||June 24, 2015|
|Submission Date||January 29, 2016|
|Submission Deemed Complete||February 5, 2016|
|Prioritization Requested||Not Requested|
|Stakeholder Input Deadline ‡||February 12, 2016|
|Check-point meeting||March 31, 2016|
|pERC Meeting||June 16, 2016|
|Initial Recommendation Issued||June 30, 2016|
|Feedback Deadline ‡||July 15, 2016|
|Final Recommendation Issued||July 19, 2016|
|Notification to Implement Issued||August 4, 2016|
|Therapeutic Area||Mantle Cell Lymphoma (relapsed/refractory)|
|Recommendation Type||Reimburse with clinical criteria and/or conditions|
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.